Advertisement

Topics

Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.

Summary of "Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report."

Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.

Affiliation

Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.

Journal Details

This article was published in the following journal.

Name: Journal of neuro-oncology
ISSN: 1573-7373
Pages:

Links

DeepDyve research library

PubMed Articles [40524 Associated PubMed Articles listed on BioPortfolio]

OS 31-05 THE IMPORTANCE OF INTER-INDIVIDUAL BLOOD PRESSURE VARIABILITY ON THE INCIDENCE OF RECURRENT STROKE: A POST HOC ANALYSIS OF ASCOT AND ALLHAT.

To evaluate differences in blood pressure variability (BPV) between patients who experience a recurrent (secondary) stroke or transient ischemic attack (TIA) compared with patients who do not have rec...

Influence of intraoperative radiation therapy on locally advanced and recurrent colorectal tumors: A 16-year experience.

Intraoperative radiation therapy (IORT) has been proposed as a tool to improve local control in patients with locally advanced primary or recurrent colorectal cancer.

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

Lenalidomide and dexamethasone are an effective treatment for naïve and relapsed multiple myeloma (MM) patients. Bendamustine is a good option for B-cell malignancies showing only partial cross resis...

Role of Expression of Inflammatory Mediators in Primary and Recurrent Lumbar Disc Herniation.

To assess role of some inflammatory mediators in patients with primary and recurrent lumbar disc herniation. Expression of IL-6, transforming growth factor (TGF)-1, insulin-like growth factor (IGF)-1,...

Safety and efficacy of Obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance with obinutuzumab alone, in previously untreated patients wit...

Clinical Trials [7024 Associated Clinical Trials listed on BioPortfolio]

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

The purpose of this study is to evaluate the safety and efficacy of Bendamustine (TREANDA™), in combination with Melphalan in subjects with multiple myeloma who are undergoing an Autolog...

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib. ...

Open Trial of Bendamustine HCL in Women With Advanced Ovarian Cancer

The study design is a non-randomized, open label, single center Phase II trial. Eligible patients are women who have a confirmed diagnosis of ovary, fallopian tube cancer or primary perit...

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

The goal of this multi-center Phase II study is to add bortezomib to the highly active regimen of bendamustine and rituximab. In this study, bortezomib will be administered on a weekly sc...

Medical and Biotech [MESH] Definitions

Providers of initial care for patients. These PHYSICIANS refer patients when appropriate for secondary or specialist care.

A condition characterized by persistent or recurrent labial enlargement, ORAL ULCER, and other orofacial manifestations in the absence of identifiable CROHN DISEASE; or SARCOIDOSIS. There is no consensus on whether orofacial granulomatosis is a distinct clinical disorder or an initial presentation of Crohn disease.

An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557)

Incision of Oddi's sphincter or Vater's ampulla performed by inserting a sphincterotome through an endoscope (DUODENOSCOPE) often following retrograde cholangiography (CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE). Endoscopic treatment by sphincterotomy is the preferred method of treatment for patients with retained or recurrent bile duct stones post-cholecystectomy, and for poor-surgical-risk patients that have the gallbladder still present.

Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli.

Quick Search
Advertisement
 


DeepDyve research library

Searches Linking to this Article